-
-
-
-
-
-
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
-
-
-
-
-
-
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat
-
-
-
-
-
-
-
FDA approves Gilead's Hepcludex as first HDV treatment in U.S.
-
-
-
-
-
-
-
Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
Gilead Sciences (GILD) PT Raised to $123 at RBC Capital
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
-
458,877 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

